It is typical to encounter a restricted number of APIs during the initial stages of drug development. This limitation hinders the swift advancement of the development process. Renejix introduces an innovative strategy that facilitates the utilization of large-scale machinery right from the outset, potentially leading to the production of cGMP batches with favorable yields.
Similar Posts
Solid State Form Characterization for Drug Development
Characterizing an API’s different salt forms and polymorphs is an essential drug development task. The successful preclinical assessment and product development can…
Small Molecule Analytical Services
This document provides both a high-level overview of Renejix’s stand-alone small molecule analytical services, and a detailed list of services organized by…
Equipment Lists
Please check out the below links to access our list of equipments available at the respective locations1. Hauppauge, New York2. Islip, New…
Solutions for Drug Development
An array of advanced technologies at your disposal to address your molecule’s challenges and processing hurdles effectively, achieving the optimal dosage form.
Early Phase Development Using Integrated Solutions
A newly formed pharmaceutical company was creating a novel cardiometabolic drug, a new small molecule, that was in Phase 2a testing in…
FormaDoseâ„¢ Design: Solution For Dosage Form Selection
FormaDose® Design Solution is a comprehensive drug design assessment consisting of a holistic review of the molecule, patient, and market considerations. Led…